ALX Oncology Holdings Inc. (ALXO) Stock Forecast
ALXO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $4.60 average of analyst targets
- Upside to target
- +334.0% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.14
- 52-week range
- $0.89 – $2.60
ALXO analyst ratings
7 analystsNumber of analysts at each rating.
ALXO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALXO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.16 | −$0.10 | −$0.41 | +67.8% | 6 |
| Current fiscal year (2026) | −$2.64 | −$3.58 | −$1.70 | −$1.66 | −59.5% | 2 |
| Next fiscal year (2027) | −$0.55 | −$0.74 | −$0.40 | −$0.56 | +2.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALXO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
ALXO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALXO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.13 | −$0.13 | −$0.13 | −11.6% | 4 up · 1 down |
| Current fiscal year (2026) | −$2.95 | −$2.65 | −$2.65 | −$2.65 | −$2.64 | −10.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.58 | −$0.58 | −$0.55 | −$0.55 | −$0.55 | −5.9% | 3 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALXO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALXO beat in 4 of 12.
What analysts expect from ALXO
7 analysts cover ALX Oncology; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.60, 334.0% above the latest close of $1.06. Analysts expect earnings of −$2.64 per share for 2026, −59.5% from a year earlier. For 2027 the average estimate is −$0.55 per share. ALX Oncology beat the EPS estimate in 4 of the last 12 quarters.
Related: ALXO income statement, ALXO key metrics, ALXO chart. See the ALXO stock overview for the latest quote and news.
ALXO forecast FAQ
What is ALX Oncology's price target?
The average analyst price target for ALX Oncology is $4.60, 334.0% above the latest close of $1.06.
Is ALX Oncology a buy, hold or sell?
Of 7 analysts covering ALX Oncology, 5 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ALX Oncology's EPS forecast?
Analysts forecast −$2.64 per share for 2026 (range −$3.58 to −$1.70); for 2027 the estimate is −$0.55.
When does ALX Oncology report earnings?
ALX Oncology is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens; the EPS estimate is $-0.14.
Does ALX Oncology usually beat earnings estimates?
ALX Oncology reported EPS at or above the analyst estimate in 4 of the last 12 quarters.